NasdaqGS:ANABBiotechs
AnaptysBio (ANAB) Losses Worsen 29.9% Annually, Undercutting Bullish Revenue Growth Narratives
AnaptysBio (ANAB) is forecasting revenue growth of 25.9% per year, ahead of the broader US market’s 10.5% growth rate. Despite this, the company remains unprofitable, with losses climbing at an annual pace of 29.9% over the past five years. Net profit margins and earnings quality have yet to show improvement. Shares currently trade at a Price-to-Sales ratio of 8.2x, which offers better value than the US Biotech sector average of 10.3x, but appears expensive relative to peers at 5.8x. This...